Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2025.218100 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Letters, 2026. Verfasst von Ping Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Immunotherapy, Chongqing, 40…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-ret, Adenocarcinoma of Lung, Lung Neoplasms, Pyrazoles. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
We report a rare case of advanced lung adenocarcinoma harboring a novel non-canonical RET::FOXJ3 gene fusion, which has not been previously documented. A 66-year-old male was diagnosed with stage IVB non-small cell lung cancer (NSCLC). Next-generation sequencing (NGS) analysis using the Illumina NovaSeq 6000 identified a previously unreported rearrangement of RET (Rearranged During Transfection) proto-oncogene, involving a fusion of RET exon 1 to FOXJ3 (Forkhead box J3) exons 2-13. Following disease progression on first-line chemotherapy combined with PD-L1 blockage (PFS1 = 6 months), the patient was treated with the selective RET inhibitor pralsetinib (PFS2 = 2 months). However, no significant clinical response was observed, and disease progression was reassessed after 6 weeks of targeted therapy. Palliative cranial radiotherapy was subsequently administered for newly developed brain metastases (PFS3 = 5 months), resulting in an overall survival of 18 months (OS = 18 months). This case expands the current understanding of RET fusion partners and raises important questions regarding the functional and therapeutic implications of non-canonical fusions. It underscores the necessity of corroborating DNA-level findings with RNA and/or protein expression data and highlights the limitations of existing RET-targeted therapies for atypical RET fusions that may lack an intact kinase domain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Immunotherapy, Chongqing, 401336, China.
- Department of Biological Sciences, Faculty of Science, National University of Singapore, 14 Science Drive 4, 117543, Singapore.
- Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Immunotherapy, Chongqing, 401336, China; Department of Biological Sciences, Faculty of Science, Na…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, P., Tang, H. X. L., Song, J., Yang, Y., Yao, Y., & Xia, L. (2026). Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218100
Vancouver
Wang P, Tang HXL, Song J, Yang Y, Yao Y, Xia L. Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib. Cancer Letters. 2026. doi:10.1016/j.canlet.2025.218100
BibTeX
@article{Wang2026,
author = {Wang, Ping and Tang, Hao Xi Lucas and Song, Jiaqin and Yang, Yuyan and Yao, Yao and Xia, Lei},
title = {Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2025.218100}
}
EUVIMED